Atacicept in Subjects With IgA Nephropathy

IgA Nephropathy Clinical Trial

— ORIGIN 3  

Official title:

A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With IgA Nephropathy (IgAN)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04716231
• Other study ID #: VT-001-0050
• Status: Recruiting
• Phase: Phase 3
• Start date: May 23, 2023
• Est. completion date: July 2028

Study information

• Verified date: June 2023
• Source: Vera Therapeutics, Inc.
• Contact: Vera Therapeutics, Inc. Clinical Trials Information
• Phone: 650-770-0077
• Email: clinicaltrials[@]veratx.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)

Description:

This is a multi-part study comprising of the original Phase 2b study (active, no longer recruiting) and the addition of a separate pivotal Phase 3 study (active, recruiting).

After the completion of the primary results for the Ph 2b dose ranging study, the pivotal study (active, recruiting) will evaluate the efficacy and safety of atacicept compared to placebo in reducing proteinuria in subjects with IgAN and persistent proteinuria despite being on a maximally tolerated dose (MTD) of a RASi. Safety, eGFR, serum immunoglobulins and Gd-IgA1 will also be clinically assessed. The clinical study is comprised of a 104wk double-blind treatment period, followed by a 52wk open-label treatment period and a 26wk safety follow-up period. The UPCR primary endpoint will be assessed after the first 200 patients are randomized.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 376
• Est. completion date: July 2028
• Est. primary completion date: May 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

• Must have the ability to understand and sign a written informed consent form

• Male or female of =18 years of age

• Total urine protein excretion =1.0 g per 24-hour or urine protein to creatinine ratio (UPCR) =1.0 mg/mg based on a 24-hour urine sample during the Screening Period

• Diagnosis of IgAN as demonstrated by renal biopsy conducted within 10 years

• eGFR = 30 mL/min/1.73 m2, as per the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

• On a stable prescribed regimen of RAASi for at least 12 weeks that is at the maximum labeled or tolerated dose at Screening

• Systolic blood pressure =150 mmHg and diastolic blood pressure =90 mmHg

Key Exclusion Criteria:

• IgAN secondary to another condition (e.g., liver cirrhosis), or other causes of mesangial IgA deposition including IgA vasculitis (i.e., Henoch-Schonlein purpura), systemic lupus erythematosus (SLE), dermatitis herpetiformis, ankylosing spondylitis

• Total urine protein excretion = 5g per 24-hour or urine protein to creatinine ratio (UPCR) = 5 mg/mg based on a 24-hour urine sample during the Screening Period

• Evidence of rapidly progressive glomerulonephritis (loss of = 50% of eGFR within 3 months of screening)

• Evidence of nephrotic syndrome within 6 months of screening (serum albumin <30g/L in association with UPCR >3.5 mg/mg

• Renal or other organ transplantation prior to, or expected during the study

• Concomitant chronic renal disease in addition to IgAN

• Uncontrolled diabetes, defined as hemoglobin-A1c (HbA1c) >7.5% at screening

• History of tuberculosis (TB), untreated latent TB infection (LTBI), or evidence of active TB determined by a positive Quantiferon test

• Participation in the Phase 2b (Parts A and B) study or any previous treatment with atacicept

Related Conditions & MeSH terms

• Berger Disease
• Glomerulonephritis, IGA
• IgA Nephropathy
• Kidney Diseases

Intervention

Biological:
• Atacicept
Once weekly subcutaneous (SC) injections by prefilled syringe

Other:
• Placebo to match Atacicept
Once weekly subcutaneous (SC) injections by prefilled syringe

Locations

Country	Name	City	State
United States	ORIGIN 3 Global Site Contact Information	Brisbane	California

Sponsors (1)

Lead Sponsor	Collaborator
Vera Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in urine protein to creatinine ratio (UPCR)	UPCR based on 24 hour urine collection	36 Weeks
Secondary	Annualized rate of change in estimated glomerular filtration rate (eGFR)	eGFR calculated by CKD-EPI formula	52 and 104 Weeks

External Links

•   ORIGIN 3 Study Website
•   Vera Therapeutics, Inc Company Website